ICON (ICLR)
(Delayed Data from NSDQ)
$323.46 USD
+10.36 (3.31%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $326.12 +2.66 (0.82%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$323.46 USD
+10.36 (3.31%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $326.12 +2.66 (0.82%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth C Momentum B VGM
Zacks News
ICON (ICLR) Gains From Strategic Deals, New Innovations
by Zacks Equity Research
ICON (ICLR) continues to evolve its collaboration and delivery models, invest in technology, and enhance its project and program management capabilities.
The Zacks Analyst Blog Highlights Apple, Meta Platforms, Intel, Brokers Group and ICON
by Zacks Equity Research
Apple, Meta Platforms, Intel, Brokers Group and ICON are included in this Analyst Blog.
Top Analyst Reports for Apple, Meta Platforms & Intel
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Meta Platforms, Inc. (META) and Intel Corporation (INTC).
Philips (PHG) Aids Diagnostic Imaging With Philips CT 5300
by Zacks Equity Research
Philips (PHG) introduces AI-enabled Philips CT 5300 X-ray CT system, expanding its diagnostic imaging portfolio.
Are You Looking for a Top Momentum Pick? Why Icon PLC (ICLR) is a Great Choice
by Zacks Equity Research
Does Icon PLC (ICLR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Waters (WAT) Boosts LC Solutions Portfolio With New Software
by Zacks Equity Research
Waters (WAT) unveils HPLC CONNECT software, bolstering its liquid chromatography solutions portfolio.
All You Need to Know About Icon PLC (ICLR) Rating Upgrade to Buy
by Zacks Equity Research
Icon PLC (ICLR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Momentum in Icon PLC (ICLR) Should Keep going
by Zacks Equity Research
Icon PLC (ICLR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.
Icon PLC (ICLR) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.58% and 0.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons Growth Investors Will Love Icon PLC (ICLR)
by Zacks Equity Research
Icon PLC (ICLR) could produce exceptional returns because of its solid growth attributes.
ICLR or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICLR vs. DOCS: Which Stock Is the Better Value Option?
Zacks.com featured highlights include Confluent, Pinterest, ICON and ImmunoGen
by Zacks Equity Research
Confluent, Pinterest, ICON and ImmunoGen are part of the Zacks Screen of the Week article.
4 Stocks to Invest in for Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Confluent (CFLT), Pinterest (PINS), ICON (ICLR) and ImmunoGen (IMGN) for solid earnings acceleration.
Here is Why Growth Investors Should Buy Icon PLC (ICLR) Now
by Zacks Equity Research
Icon PLC (ICLR) possesses solid growth attributes, which could help it handily outperform the market.
Icon PLC (ICLR) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.61% and 0.29%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICLR vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
ICLR vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
ICLR or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
Icon PLC (ICLR) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.97% and 0.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ICLR or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
Icon PLC (ICLR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Icon PLC (ICLR) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of -2.68% and 0.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth (UNH) Buys Crystal Run to Boost Value-Based Care
by Zacks Equity Research
UnitedHealth Group (UNH) acquires Crystal Run, as per multiple reports. The move tends to offer enhanced value-based care across the Hudson Valley and lower Catskill region.